Arvinas' vepdegestrant shows 43% reduced risk of progression or death in ESR1-mutated breast cancer patients vs hormone ...

Immatics has shared new survival data from a Phase 1b trial of its melanoma cell therapy candidate, bolstering expectations for a registrational study that it recently started.

Wel­come to End­points News’ man­u­fac­tur­ing briefs, where we bring you es­sen­tial news on new builds, col­lab­o­ra­tions, re­calls and more.

After a slight delay, the FDA rejected Stealth BioTherapeutics' Barth syndrome drug application for elamipretide, but will ...

For Illumina, its former employees are both a boon and a problem. In the 27 years since its founding, the DNA sequencing ...

Summit Therapeutics’ mixed results for its potential competitor to Merck’s Keytruda left an important question unanswered: ...

The US Supreme Court will continue deciding whether to take up a pivotal case on state PBM regulation after the federal ...

Biopharma faces uncertainty in H2 2025 amid policy concerns and market challenges, with key healthcare conferences and medical meetings ahead to provide industry direction.

Intellia Therapeutics reports serious liver enzyme elevation in one patient during Phase 3 trial of nex-z gene editing therapy for ATTR cardiomyopathy; shares drop 26% ...

Eli Lil­ly’s ex­per­i­men­tal weight loss drug ap­pears to have set a new bar, help­ing obese pa­tients in a Phase II study lose 24% of their … ...

Ei­sai has slashed 2027 sales pro­jec­tions for its Bio­gen-part­nered Alzheimer’s treat­ment Leqem­bi by rough­ly half.